The holiday season can be a stressful time for many, but for the nearly 12 million family members and friends serving as unpaid caregivers of people living with Alzheimer’s and dementia, the holidays can be especially challenging.
On July 6, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
